Arilin 250 mg apvalkotās tabletes un 100 mg pesāriji, kombinēts iepakojums Latvia - latvia - Zāļu valsts aģentūra

arilin 250 mg apvalkotās tabletes un 100 mg pesāriji, kombinēts iepakojums

dr. august wolff gmbh & co. kg arzneimittel, germany - metronidazols - apvalkotā tablete + pesārijs - 250 mg/100 mg

Arilin 100 mg pesāriji Latvia - latvia - Zāļu valsts aģentūra

arilin 100 mg pesāriji

dr. august wolff gmbh & co. kg arzneimittel, germany - metronidazols - pesārijs - 100 mg

Arilin rapid 1000 mg pesāriji Latvia - latvia - Zāļu valsts aģentūra

arilin rapid 1000 mg pesāriji

dr. august wolff gmbh & co. kg arzneimittel, germany - metronidazols - pesārijs - 1000 mg

Versatis 700 mg ārstnieciskais plāksteris Latvia - latvia - Zāļu valsts aģentūra

versatis 700 mg ārstnieciskais plāksteris

grünenthal gmbh, germany - lidokaīns - Ārstnieciskais plāksteris - 700 mg

Comirnaty Euroopan unioni - latvia - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Ascorbic Acid Pascoe 150 mg/ml koncentrāts injekciju/infūziju šķīduma pagatavošanai Latvia - latvia - Zāļu valsts aģentūra

ascorbic acid pascoe 150 mg/ml koncentrāts injekciju/infūziju šķīduma pagatavošanai

pascoe pharmazeutische praeparate gmbh, germany - skābes ascorbicum - koncentrāts injekciju/infūziju šķīduma pagatavošanai - 150 mg/ml

Travoprost/Timolol Mylan 40 mikrogrami/ml + 5 mg/ml acu pilieni, šķīdums Latvia - latvia - Zāļu valsts aģentūra

travoprost/timolol mylan 40 mikrogrami/ml + 5 mg/ml acu pilieni, šķīdums

mylan pharmaceuticals limited, ireland - travoprostum, timololum - acu pilieni, šķīdums - 40 µg/ml + 5 mg/ml

Obizur Euroopan unioni - latvia - EMA (European Medicines Agency)

obizur

baxalta innovations gmbh - susoctocog alfa - a hemofīlija - antihemorāģija - asiņošanas epizožu ārstēšana pacientiem ar iegūto hemofiliju, ko izraisa antivielas pret viii faktoru. obizur ir indicēts pieaugušajiem.

Febuxostat Mylan Euroopan unioni - latvia - EMA (European Medicines Agency)

febuxostat mylan

mylan pharmaceuticals limited - febuxostat - hyperuricemia; arthritis, gouty; gout - antigut preparāti - febuxostat mylan indicēts profilaksi un ārstēšanu pieaugušiem pacientiem veikta ķīmijterapija haematologic malignancies starpproduktu ar augsta riska audzēju līzes sindroms (tls) hyperuricaemia. febuxostat mylan ir indicēts, lai ārstētu hronisku hyperuricaemia apstākļos, kad urate uzklāšanas jau ir noticis (tai skaitā vēsturē, vai klātbūtne, tophus un/vai podagras artrīta). febuxostat mylan ir norādīts pieaugušie.

Rienso Euroopan unioni - latvia - EMA (European Medicines Agency)

rienso

takeda pharma a/s - ferumoksitols - anemia; kidney failure, chronic - citi antianēmiskie līdzekļi - rienso ir indicēts dzelzs deficīta anēmijas intravenozai ārstēšanai pieaugušiem pacientiem ar hronisku nieru slimību (ckd). diagnozi par dzelzs deficītu, ir jābūt balstītai uz atbilstošu laboratorijas testu (skatīt 4. iedaļu.